Company
Selected Our Projects in the past
The 25rd Annual Meeting of the Japan Society for Science Policy and Research Management
Date: October 10, 2010      Venue: Asia University, Tokyo JAPAN
Title (2D02):  New Waves in Biotechnology that Enable to Embody the Personalized Medicine in the Near Future - how the Japanese should think of generating new healthcare industry in Japan?
The 29th Annual Meeting of the Japan Society of Clinical Pharmacology and Therapeutics
Date: December 4, 2008      Venue: Keio Plaza Hotel, Shinjuku, Tokyo JAPAN
Title (S2-1): S2-1: US-Trends on the Business and the Technology Development based on the Genetic Information for Personalized Medicine
Summary:
Although the practical results from the research to clarify the correlation between diseases and genes and/or genes and drugs (pharmacogenomics and pharmacogenetics) have not been recognized many so far, the development of the diagnostic instrumentation and business based on the genetetic information has been in progress urgently. In the US market, Genetic Analysis Services business, such as congenital hereditary disease, SNPs (single nucleotide polymorphism) & genotype analyses for the reactiveness to a specific drug, identification of cancer type, prognosis of the recurrence of the breast cancer, prognosis of the acute rejection of heart transplantation (multi-gene expression profiling) has emerged currently. On the other hand, whole genome read-through technologies also have come on the market.
The development of diagnostic instrumentation is required as quick, easy, precise, inexpensive, and small, at such as 'point-of-care' and 'lab-on-chip' which includes nanotechnology, microfluidics and biochip on the market.
In this paper, this kind of novel emerging technologies and new business in the US trends will be summarized and discussed.
Copyright © 2009-2015 Rainbow BioScience, LLC. All Rights Reserved.